Telix Pharmaceuticals Reports 2026 Annual General Meeting Results and Presentations

Telix Pharmaceuticals Limited (the \"Company\") has filed a Form 6-K reporting the results of its Annual General Meeting (AGM) held on May 21, 2026. The filing includes three key exhibits originally announced on the Australian Securities Exchange (ASX): the Chairman and CEO's formal addresses to shareholders, the comprehensive AGM presentation, and the final voting results of the meeting. The addresses and presentation typically provide an overview of the company's strategic progress, financial performance, and updates on its radiopharmaceutical pipeline, while the results document confirms shareholder approval for various corporate resolutions. No specific new clinical trial data or regulatory milestones were detailed in the primary 6-K text beyond the occurrence and outcomes of the shareholder meeting. Christian Krautkramer, Group General Counsel, signed the report on behalf of the Company.